HK1043113A1 - Telomerase inhibitors and methods of their use - Google Patents

Telomerase inhibitors and methods of their use

Info

Publication number
HK1043113A1
HK1043113A1 HK02102943.2A HK02102943A HK1043113A1 HK 1043113 A1 HK1043113 A1 HK 1043113A1 HK 02102943 A HK02102943 A HK 02102943A HK 1043113 A1 HK1043113 A1 HK 1043113A1
Authority
HK
Hong Kong
Prior art keywords
methods
telomerase inhibitors
telomerase
inhibitors
Prior art date
Application number
HK02102943.2A
Other languages
Chinese (zh)
Inventor
C Chin Allison
Holcomb Ryan
A Piatyszek Mieczyslaw
Singh Upinder
L Tolman Richard
Akama Tsutomu
Kanda Yutaka
Asai Akira
Yamashita Yoshinori
Endo Kaori
Yamaguchi Hiroyuki
Original Assignee
Geron Corp
Kyowa Hakko Kogyo Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP30757699A external-priority patent/JP2001072592A/en
Application filed by Geron Corp, Kyowa Hakko Kogyo Kk filed Critical Geron Corp
Publication of HK1043113A1 publication Critical patent/HK1043113A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
HK02102943.2A 1999-07-01 2002-04-18 Telomerase inhibitors and methods of their use HK1043113A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US14217399P 1999-07-01 1999-07-01
JP18761699 1999-07-01
JP30757699A JP2001072592A (en) 1999-07-01 1999-10-28 Telomerase inhibitor
PCT/US2000/018211 WO2001002377A1 (en) 1999-07-01 2000-06-30 Telomerase inhibitors and methods of their use

Publications (1)

Publication Number Publication Date
HK1043113A1 true HK1043113A1 (en) 2002-09-06

Family

ID=27325921

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02102943.2A HK1043113A1 (en) 1999-07-01 2002-04-18 Telomerase inhibitors and methods of their use

Country Status (9)

Country Link
EP (1) EP1109796A1 (en)
JP (1) JP2003507473A (en)
KR (1) KR20010099634A (en)
CN (1) CN1321153A (en)
AU (1) AU6340600A (en)
CA (1) CA2341253A1 (en)
HK (1) HK1043113A1 (en)
ID (1) ID29875A (en)
WO (1) WO2001002377A1 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7026334B1 (en) * 1999-07-26 2006-04-11 Shionogi & Co., Ltd. Thiazolidine compounds and pharmaceutical compositions exhibiting thrombopoietin receptor agonism
US6620830B2 (en) 2000-04-21 2003-09-16 Pfizer, Inc. Thyroid receptor ligands
EP1148054B1 (en) * 2000-04-21 2005-11-23 Pfizer Products Inc. Thyroid receptor ligands
WO2001081328A2 (en) * 2000-04-24 2001-11-01 Aryx Therapeutics Thiazolidinedione analogues and their use for the treatment of diabetes
US6768008B2 (en) 2000-04-24 2004-07-27 Aryx Therapeutics Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
US6680387B2 (en) 2000-04-24 2004-01-20 Aryx Therapeutics Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
US6958355B2 (en) 2000-04-24 2005-10-25 Aryx Therapeutics, Inc. Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
AU2001294673A1 (en) 2000-09-21 2002-04-02 Aryx Therapeutics Isoxazolidine compounds useful in the treatment of diabetes, hyperlipidemia, andatherosclerosis
DE10133665A1 (en) * 2001-07-11 2003-01-30 Boehringer Ingelheim Pharma Carboxylic acid derivatives, medicaments containing these compounds, their use and preparation
WO2003018011A1 (en) * 2001-08-24 2003-03-06 Wyeth Holdings Corporation 5-(substituted)-5-(substitutedsulfonyl or sulfanyl)thiazolidine-2,4-diones useful for inhibition of farnesyl-protein transferase
US7045523B2 (en) 2001-10-18 2006-05-16 Novartis Ag Combination comprising N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and telomerase inhibitor
GB0204252D0 (en) * 2002-02-23 2002-04-10 Oxford Glycosciences Uk Ltd Novel compounds
EP1551396A1 (en) * 2002-09-26 2005-07-13 Pintex Pharmaceuticals, Inc. Pin1-modulating compounds and methods of use thereof
US6794401B2 (en) 2003-01-17 2004-09-21 Bexel Pharmaceuticals, Inc. Amino acid phenoxy ethers
US7781464B2 (en) * 2003-01-17 2010-08-24 Bexel Pharmaceuticals, Inc. Heterocyclic diphenyl ethers
US7521465B2 (en) 2003-01-17 2009-04-21 Bexel Pharmaceuticals, Inc. Diphenyl ether derivatives
WO2004093803A2 (en) * 2003-04-16 2004-11-04 Pintex Pharmaceuticals, Inc. Photochemotherapeutic compounds for use in treatment of pin1-associated states
US7087576B2 (en) 2003-10-07 2006-08-08 Bexel Pharmaceuticals, Inc. Dipeptide phenyl ethers
FI20041129A0 (en) * 2004-08-30 2004-08-30 Ctt Cancer Targeting Tech Oy Thioxothiazolidinone compounds for use as drugs
EP1797082B1 (en) 2004-09-28 2012-08-29 Otsuka Pharmaceutical Co., Ltd. Carbostyril compound
FR2887444A1 (en) * 2005-06-28 2006-12-29 Oreal BENZYLIDENE-1,3-THIAZOLIDINE-2,4-DIONES COMPOUNDS, THEIR USES AND COMPOSITIONS FOR STIMULATING OR INDUCING THE PUSH OF KERATIN FIBERS AND / OR BRAKING THEIR FALL AND / OR INCREASING THEIR DENSITY
KR100814109B1 (en) * 2006-01-09 2008-03-14 한국생명공학연구원 Rhodanine derivatives, a process for the preparation thereof and pharmaceutical composition containing the same
TWI315304B (en) * 2006-08-31 2009-10-01 Univ Taipei Medical Indoline-sulfonamides compounds
TW200902507A (en) * 2007-03-07 2009-01-16 Janssen Pharmaceutica Nv Substituted phenoxy n-alkylated thiazolidinediones as estrogen related receptor-α modulators
US20110263664A1 (en) * 2007-11-15 2011-10-27 Musc Foundation For Research Development Inhibitors of PIM-1 Protein Kinases, Compositions and Methods for Treating Prostate Cancer
TWI461423B (en) 2008-07-02 2014-11-21 Astrazeneca Ab Thiazolidinedione compounds useful in the treatment of pim kinase related conditions and diseases
CN101973893B (en) * 2010-09-07 2013-07-17 黑龙江省科学院石油化学研究院 Synthesis method of 4-[2-(1-styryl)]-N,N-di(4-bromomethy) aniline
KR101817287B1 (en) * 2016-01-08 2018-01-10 조선대학교 산학협력단 Thiazolidinedione derivative and use thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) * 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
JPS5697277A (en) * 1980-01-07 1981-08-05 Takeda Chem Ind Ltd Thiazolidine derivative
JPS58118577A (en) * 1982-01-07 1983-07-14 Takeda Chem Ind Ltd Thiazolidine derivative
CN1003445B (en) * 1984-10-03 1989-03-01 武田药品工业株式会社 The preparation method of thiazolidine diketone derivative
AR240698A1 (en) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Process for the preparation of 5-(4-(2-(5-ethyl-2-pyridil)-ethoxy)benzyl)-2,4-thiazolodinedione and their salts
US4738972A (en) * 1985-05-21 1988-04-19 Pfizer Inc. Hypoglycemic thiazolidinediones
US4812570A (en) * 1986-07-24 1989-03-14 Takeda Chemical Industries, Ltd. Method for producing thiazolidinedione derivatives
MX15171A (en) * 1988-03-08 1993-05-01 Pfizer DERIVATIVES OF TIAZOLIDINODIONA HIPOGLICEMICOS
WO1989008650A1 (en) * 1988-03-08 1989-09-21 Pfizer Inc. Thiazolidinedione hypoglycemic agents
IE62214B1 (en) * 1988-05-25 1995-01-11 Warner Lambert Co Arylmethylenyl derivatives of thiazolidinones, imidazolidinones and oxazolidinones useful as antiallergy agents and antiinflammatory agents
US5143929A (en) * 1991-05-09 1992-09-01 Warner-Lambert Company 2-substituted thiazolidinone, oxazolidinone, and imidazolidinone derivatives of fenamates as antiinflammatory agents
US6251928B1 (en) * 1994-03-16 2001-06-26 Eli Lilly And Company Treatment of alzheimer's disease employing inhibitors of cathepsin D
US5814647A (en) * 1997-03-04 1998-09-29 Board Of Regents, The University Of Texas System Use of troglitazone and related compounds for the treatment of the climacteric symptoms

Also Published As

Publication number Publication date
JP2003507473A (en) 2003-02-25
AU6340600A (en) 2001-01-22
CA2341253A1 (en) 2001-01-11
CN1321153A (en) 2001-11-07
ID29875A (en) 2001-10-18
KR20010099634A (en) 2001-11-09
WO2001002377A1 (en) 2001-01-11
EP1109796A1 (en) 2001-06-27
WO2001002377A9 (en) 2001-10-11

Similar Documents

Publication Publication Date Title
HK1043113A1 (en) Telomerase inhibitors and methods of their use
GB2374100B (en) Underreamer and method of use
HK1048247A1 (en) Stable carotene-xanthophyll beadlet compositions and methods of use
AU7593001A (en) Alpha-msh related compounds and methods of use
IL148657A0 (en) Stent range transducers and methods of use
IL144214A0 (en) Benzoheterocycles and their use as mek inhibitors
HK1068874A1 (en) Heterocyclic compounds and methods of use
EP1227821A4 (en) Therapeutic compositions and methods of use thereof
EP1448218A4 (en) Beta-secretase inhibitors and methods of use
IL146000A0 (en) Ace-2 inhibiting compounds and methods of use thereof
AU2002225954A1 (en) Dipeptidylpeptidases and methods of use
EP1183030A4 (en) Methods of making and using n-desmethylzopiclone
AU1334602A (en) Osteopontin-coated surfaces and methods of use
AU2002213346A1 (en) Osteopontin-coated surfaces and methods of use
GB2367103B (en) Connector and method of use of the connector
PL361733A1 (en) Sulfamidothienopyrimidines and the use of the same as phosphodiesterase v inhibitors
AU2001255696A1 (en) Telomerase inhibitors and methods of their use
AU2002363938A8 (en) Methods and use of motoneuronotropic factors
HUP0204376A3 (en) Novel invertase inhibitors and methods of use
IL152792A0 (en) Heterocycle derivatives and methods of use
EP1161451A4 (en) Human endokine alpha and methods of use
EP1263935A4 (en) Scytonemin and methods of using thereof
AU2002306845A1 (en) Telomerase inhibitors and methods of their use
AU2001275381A1 (en) Telomerase inhibitors and methods of their use
SG90719A1 (en) Novel therapeutic and prophylactic agents and methods of using same